Chicago Equity Partners LLC purchased a new position in PetMed Express, Inc. (NASDAQ:PETS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 8,180 shares of the company’s stock, valued at approximately $271,000.
A number of other large investors have also bought and sold shares of PETS. Pinebridge Investments L.P. raised its position in PetMed Express by 1.0% during the second quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after purchasing an additional 27 shares in the last quarter. Acrospire Investment Management LLC purchased a new stake in PetMed Express during the second quarter valued at about $110,000. Fred Alger Management Inc. purchased a new stake in PetMed Express during the second quarter valued at about $162,000. State of Alaska Department of Revenue raised its position in PetMed Express by 76.7% during the second quarter. State of Alaska Department of Revenue now owns 4,028 shares of the company’s stock valued at $163,000 after purchasing an additional 1,748 shares in the last quarter. Finally, Bayesian Capital Management LP purchased a new stake in PetMed Express during the second quarter valued at about $203,000. 99.91% of the stock is owned by institutional investors.
PetMed Express, Inc. (NASDAQ:PETS) traded up $1.58 on Monday, hitting $40.92. The stock had a trading volume of 665,909 shares, compared to its average volume of 650,842. The stock has a market capitalization of $843.13, a P/E ratio of 26.40, a P/E/G ratio of 2.36 and a beta of 1.13. PetMed Express, Inc. has a 1 year low of $19.21 and a 1 year high of $50.90.
PetMed Express (NASDAQ:PETS) last posted its earnings results on Monday, October 23rd. The company reported $0.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.13. The company had revenue of $66.70 million for the quarter, compared to analysts’ expectations of $63.41 million. PetMed Express had a return on equity of 31.46% and a net margin of 11.58%. PetMed Express’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm earned $0.24 earnings per share. research analysts predict that PetMed Express, Inc. will post 1.67 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, November 17th. Shareholders of record on Monday, November 6th were given a dividend of $0.20 per share. The ex-dividend date was Friday, November 3rd. This represents a $0.80 annualized dividend and a yield of 1.96%. PetMed Express’s payout ratio is 53.69%.
A number of research firms have weighed in on PETS. Craig Hallum restated a “hold” rating and set a $40.00 price target (down previously from $43.00) on shares of PetMed Express in a research report on Monday, August 21st. They noted that the move was a valuation call. Credit Suisse Group reiterated an “underperform” rating and issued a $19.00 price objective on shares of PetMed Express in a report on Monday, October 2nd. Noble Financial reiterated a “hold” rating on shares of PetMed Express in a report on Friday, October 27th. BidaskClub downgraded PetMed Express from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 22nd. Finally, ValuEngine downgraded PetMed Express from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $42.00.
In other PetMed Express news, Director Ronald J. Korn sold 1,000 shares of PetMed Express stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $35.57, for a total transaction of $35,570.00. Following the sale, the director now directly owns 73,833 shares of the company’s stock, valued at approximately $2,626,239.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/04/chicago-equity-partners-llc-takes-position-in-petmed-express-inc-pets.html.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.